Filing Details

Accession Number:
0001209191-22-060585
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-09 19:37:34
Reporting Period:
2022-12-06
Accepted Time:
2022-12-09 19:37:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
25743 Therapeuticsmd Inc. TXMD Pharmaceutical Preparations (2834) 870233535
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1627810 C Michael Donegan 951 Yamato Road
Suite 220
Boca Raton FL 33431
Interim Cfo/Cao/Vp Of Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-06 2,300 $0.00 4,288 No 4 M Direct
Common Stock Acquisiton 2022-12-06 380 $0.00 4,668 No 4 M Direct
Common Stock Acquisiton 2022-12-06 534 $0.00 5,202 No 4 M Direct
Common Stock Acquisiton 2022-12-06 262 $0.00 5,464 No 4 M Direct
Common Stock Disposition 2022-12-06 910 $4.78 4,554 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2022-12-06 2,300 $0.00 2,300 $0.00
Common Stock Restricted Stock Units Disposition 2022-12-06 380 $0.00 380 $0.00
Common Stock Restricted Stock Units Disposition 2022-12-06 534 $0.00 534 $0.00
Common Stock Restricted Stock Units Disposition 2022-12-06 262 $0.00 262 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
380 No 4 M Direct
1,066 No 4 M Direct
519 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).
  2. The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
  4. The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022.
  5. The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
  6. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.
  7. Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.